{"id":479465,"date":"2021-04-21T08:04:01","date_gmt":"2021-04-21T12:04:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/altavant-sciences-highlights-pipeline-progress-in-pah-and-bos-at-the-international-society-for-heart-lung-transplantation-meeting\/"},"modified":"2021-04-21T08:04:01","modified_gmt":"2021-04-21T12:04:01","slug":"altavant-sciences-highlights-pipeline-progress-in-pah-and-bos-at-the-international-society-for-heart-lung-transplantation-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/altavant-sciences-highlights-pipeline-progress-in-pah-and-bos-at-the-international-society-for-heart-lung-transplantation-meeting\/","title":{"rendered":"Altavant Sciences Highlights Pipeline Progress in PAH and BOS at the International Society for Heart & Lung Transplantation Meeting"},"content":{"rendered":"
\n

Cary, N.C. and Basel, Switzerland, April 21, 2021 (GLOBE NEWSWIRE) — \u2013 Altavant Sciences<\/a>, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, announced today that the company would be presenting information on its two pipeline candidates, ALTA-2530 and rodatristat ethyl, at the upcoming virtual meeting of the International Society for Heart & Lung Transplantation (ISHLT) being held April 24-28, 2021.<\/p>\n

\u00a0<\/p>\n

Results of in vivo<\/i> studies measuring lung exposure of a novel nebulized formulation of ALTA-2530, a IL-1 receptor antagonist (IL-1Ra) in development for the treatment of bronchiolitis obliterans syndrome<\/a> (BOS), will be presented in a poster (#936) at ISHLT titled: Inhalation of IL-1 Receptor Antagonist (ALTA-2530) Achieves Stable and Prolonged Pulmonary Exposure in Nonclinical Studies Supportive of Development for Bronchiolitis Obliterans Syndrome<\/u>. Sustained exposure to the distal regions of the lungs is an important consideration for the efficacious treatment of BOS. Further, treatment via a handheld nebulizer may provide a convenient portable intervention option for lung transplant patients experiencing BOS. Poster 936 will be available on demand from April 24 \u2013 July 28, 2021 on the ISHLT virtual platform in the session: \u201cLung Posters: Pharmacology and Therapeutics\u201d and will be available on the Altavant website following the conference embargo.<\/p>\n

\u00a0<\/p>\n

BOS is a life-threatening form of CLAD, commonly observed following lung transplantation. The condition is caused by an unchecked upregulation of pro-inflammatory chemical signals, including interleukin-1 (IL-1), which leads to fibrosis of the small airways (bronchioles) and eventual partial or total obstruction of the airways. ALTA-2530, a recombinant human IL-1Ra, binds competitively to the IL-1 receptor to attenuate the inflammatory response. ALTA-2530 is currently in preclinical development at Altavant for the treatment of BOS and chemical lung injuries.<\/p>\n

\u00a0<\/p>\n

In addition, Altavant will be hosting a non-CME symposium on April 25, 2021 from 2:30 – 3:30 p.m. Eastern Time, entitled: Serotonin Pathobiology in Pulmonary Arterial Hypertension (PAH) and Phase 2b Investigation of the Novel Therapy Rodatristat Ethyl (RE) in WHO Group 1 PAH<\/u>. Altavant is currently screening patients for enrollment in a Phase 2b study (NCT identifier: NCT04712669<\/a>) of rodatristat ethyl for the treatment of PAH<\/a>, a rare lung disorder driven by excessive production of peripheral serotonin. Rodatristat works by inhibiting the production of peripheral serotonin with the goal of preventing and potentially reversing the arterial remodeling that restricts blood flow in patients with PAH. This mechanism of action will be reviewed during the ISHLT symposium, which may be accessed from the society\u2019s virtual meeting platform.\u00a0 Investigators interested in learning more about this ongoing Phase 2b study, which includes clinical sites in US, Canada, and Europe, are encouraged to join this presentation.<\/p>\n

\u00a0<\/p>\n

\n About Altavant Sciences
<\/b>Altavant Sciences is a clinical-stage biopharmaceutical company focused on elevating patient-centric drug development in rare respiratory diseases. Altavant is currently advancing two pipeline candidates:\u00a0rodatristat\u00a0ethyl and\u00a0ALTA-2530<\/a>. Rodatristat, a tryptophan hydroxylase (TPH) inhibitor, may play a role in halting or reversing the vascular remodeling associated with PAH, offering a novel treatment option for patients living with this disease. Rodatristat ethyl is in Phase 2 development for patients with pulmonary arterial hypertension (PAH). ALTA-2530 is a recombinant human interleukin-1 receptor antagonist under development for bronchiolitis obliterans syndrome (BOS), a life-threatening form of chronic lung allograft dysfunction (CLAD) that frequently presents following lung transplantation. ALTA-2530’s unique mechanism of action may offer a novel treatment option for patients who suffer from BOS, a disease where there are currently no approved therapies.<\/p>\n

\u00a0<\/p>\n

Altavant is a wholly owned subsidiary of Sumitovant Biopharma Ltd. For more information, please visit\u00a0https:\/\/altavant.com<\/a>.\u00a0<\/p>\n

\n \u00a0<\/b>\n <\/p>\n

\n About Sumitovant Biopharma\u00a0Ltd.
<\/b>Sumitovant is a global biopharmaceutical company with offices in\u00a0New York City\u00a0and\u00a0London. Sumitovant is a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. Sumitovant is the majority shareholder of Myovant, and wholly owns Enzyvant, Spirovant, Urovant and\u00a0Altavant. Sumitovant’s\u00a0pipeline is comprised of early- through late-stage investigational medicines across a range of disease areas targeting high unmet need.<\/p>\n

\u00a0<\/p>\n

Sumitovant Biopharma Ltd. is a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. For further information about Sumitovant please visit\u00a0https:\/\/www.sumitovant.com\/<\/a>.\u00a0<\/p>\n

\n \u00a0<\/b>\n <\/p>\n

\n About Sumitomo Dainippon Pharma Co., Ltd.
<\/b>Sumitomo Dainippon Pharma is among the top-ten listed pharmaceutical companies in\u00a0Japan, operating globally in major pharmaceutical markets, including\u00a0Japan, the U.S.,\u00a0China\u00a0and the European Union. Sumitomo Dainippon Pharma is based on the merger in 2005 between Dainippon Pharmaceutical Co., Ltd., and Sumitomo Pharmaceuticals Co., Ltd. Today, Sumitomo Dainippon Pharma has more than 6,000 employees worldwide. Additional information about Sumitomo Dainippon Pharma is available through its corporate website at\u00a0https:\/\/www.ds-pharma.com\/<\/a>.<\/p>\n

\n \u00a0<\/b>\n <\/p>\n

\n Forward-Looking Statements
<\/b>
\n This press release contains “forward-looking statements” concerning the development and commercialization of Altavant’s products, the company’s business development efforts and its expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Altavant undertakes no obligation to update any forward-looking statements for any reason.<\/i>\n <\/p>\n


\n
\n \n <\/div>\n

\n
Aline Sherwood\r\nAltavant Sciences\r\nasherwood@scientapr.com\r\n<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"
Cary, N.C. and Basel, Switzerland, April 21, 2021 (GLOBE NEWSWIRE) — \u2013 Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, announced today that the company would be presenting information on its two pipeline candidates, ALTA-2530 and rodatristat ethyl, at the upcoming virtual meeting of the International Society for Heart & Lung Transplantation (ISHLT) being held April 24-28, 2021. \u00a0 Results of in vivo studies measuring lung exposure of a novel nebulized formulation of ALTA-2530, a IL-1 receptor antagonist (IL-1Ra) in development for the treatment of bronchiolitis obliterans syndrome (BOS), will be presented in a poster (#936) at ISHLT titled: Inhalation of IL-1 Receptor Antagonist (ALTA-2530) Achieves Stable and Prolonged Pulmonary Exposure in Nonclinical … <\/p>\n
Continue reading “Altavant Sciences Highlights Pipeline Progress in PAH and BOS at  the International Society for Heart & Lung Transplantation Meeting”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-479465","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAltavant Sciences Highlights Pipeline Progress in PAH and BOS at the International Society for Heart & Lung Transplantation Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/altavant-sciences-highlights-pipeline-progress-in-pah-and-bos-at-the-international-society-for-heart-lung-transplantation-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Altavant Sciences Highlights Pipeline Progress in PAH and BOS at the International Society for Heart & Lung Transplantation Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Cary, N.C. and Basel, Switzerland, April 21, 2021 (GLOBE NEWSWIRE) — \u2013 Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, announced today that the company would be presenting information on its two pipeline candidates, ALTA-2530 and rodatristat ethyl, at the upcoming virtual meeting of the International Society for Heart & Lung Transplantation (ISHLT) being held April 24-28, 2021. \u00a0 Results of in vivo studies measuring lung exposure of a novel nebulized formulation of ALTA-2530, a IL-1 receptor antagonist (IL-1Ra) in development for the treatment of bronchiolitis obliterans syndrome (BOS), will be presented in a poster (#936) at ISHLT titled: Inhalation of IL-1 Receptor Antagonist (ALTA-2530) Achieves Stable and Prolonged Pulmonary Exposure in Nonclinical … Continue reading "Altavant Sciences Highlights Pipeline Progress in PAH and BOS at the International Society for Heart & Lung Transplantation Meeting"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/altavant-sciences-highlights-pipeline-progress-in-pah-and-bos-at-the-international-society-for-heart-lung-transplantation-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-21T12:04:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMDc0MiM0MTMxMzU3IzIxOTc3MzE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altavant-sciences-highlights-pipeline-progress-in-pah-and-bos-at-the-international-society-for-heart-lung-transplantation-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altavant-sciences-highlights-pipeline-progress-in-pah-and-bos-at-the-international-society-for-heart-lung-transplantation-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Altavant Sciences Highlights Pipeline Progress in PAH and BOS at the International Society for Heart & Lung Transplantation Meeting\",\"datePublished\":\"2021-04-21T12:04:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altavant-sciences-highlights-pipeline-progress-in-pah-and-bos-at-the-international-society-for-heart-lung-transplantation-meeting\\\/\"},\"wordCount\":841,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altavant-sciences-highlights-pipeline-progress-in-pah-and-bos-at-the-international-society-for-heart-lung-transplantation-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyMDc0MiM0MTMxMzU3IzIxOTc3MzE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altavant-sciences-highlights-pipeline-progress-in-pah-and-bos-at-the-international-society-for-heart-lung-transplantation-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altavant-sciences-highlights-pipeline-progress-in-pah-and-bos-at-the-international-society-for-heart-lung-transplantation-meeting\\\/\",\"name\":\"Altavant Sciences Highlights Pipeline Progress in PAH and BOS at the International Society for Heart & Lung Transplantation Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altavant-sciences-highlights-pipeline-progress-in-pah-and-bos-at-the-international-society-for-heart-lung-transplantation-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altavant-sciences-highlights-pipeline-progress-in-pah-and-bos-at-the-international-society-for-heart-lung-transplantation-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyMDc0MiM0MTMxMzU3IzIxOTc3MzE=\",\"datePublished\":\"2021-04-21T12:04:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altavant-sciences-highlights-pipeline-progress-in-pah-and-bos-at-the-international-society-for-heart-lung-transplantation-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altavant-sciences-highlights-pipeline-progress-in-pah-and-bos-at-the-international-society-for-heart-lung-transplantation-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altavant-sciences-highlights-pipeline-progress-in-pah-and-bos-at-the-international-society-for-heart-lung-transplantation-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyMDc0MiM0MTMxMzU3IzIxOTc3MzE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyMDc0MiM0MTMxMzU3IzIxOTc3MzE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altavant-sciences-highlights-pipeline-progress-in-pah-and-bos-at-the-international-society-for-heart-lung-transplantation-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Altavant Sciences Highlights Pipeline Progress in PAH and BOS at the International Society for Heart & Lung Transplantation Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Altavant Sciences Highlights Pipeline Progress in PAH and BOS at the International Society for Heart & Lung Transplantation Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/altavant-sciences-highlights-pipeline-progress-in-pah-and-bos-at-the-international-society-for-heart-lung-transplantation-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Altavant Sciences Highlights Pipeline Progress in PAH and BOS at the International Society for Heart & Lung Transplantation Meeting - Market Newsdesk","og_description":"Cary, N.C. and Basel, Switzerland, April 21, 2021 (GLOBE NEWSWIRE) — \u2013 Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, announced today that the company would be presenting information on its two pipeline candidates, ALTA-2530 and rodatristat ethyl, at the upcoming virtual meeting of the International Society for Heart & Lung Transplantation (ISHLT) being held April 24-28, 2021. \u00a0 Results of in vivo studies measuring lung exposure of a novel nebulized formulation of ALTA-2530, a IL-1 receptor antagonist (IL-1Ra) in development for the treatment of bronchiolitis obliterans syndrome (BOS), will be presented in a poster (#936) at ISHLT titled: Inhalation of IL-1 Receptor Antagonist (ALTA-2530) Achieves Stable and Prolonged Pulmonary Exposure in Nonclinical … Continue reading \"Altavant Sciences Highlights Pipeline Progress in PAH and BOS at the International Society for Heart & Lung Transplantation Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/altavant-sciences-highlights-pipeline-progress-in-pah-and-bos-at-the-international-society-for-heart-lung-transplantation-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-21T12:04:01+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMDc0MiM0MTMxMzU3IzIxOTc3MzE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altavant-sciences-highlights-pipeline-progress-in-pah-and-bos-at-the-international-society-for-heart-lung-transplantation-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altavant-sciences-highlights-pipeline-progress-in-pah-and-bos-at-the-international-society-for-heart-lung-transplantation-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Altavant Sciences Highlights Pipeline Progress in PAH and BOS at the International Society for Heart & Lung Transplantation Meeting","datePublished":"2021-04-21T12:04:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altavant-sciences-highlights-pipeline-progress-in-pah-and-bos-at-the-international-society-for-heart-lung-transplantation-meeting\/"},"wordCount":841,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altavant-sciences-highlights-pipeline-progress-in-pah-and-bos-at-the-international-society-for-heart-lung-transplantation-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMDc0MiM0MTMxMzU3IzIxOTc3MzE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altavant-sciences-highlights-pipeline-progress-in-pah-and-bos-at-the-international-society-for-heart-lung-transplantation-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/altavant-sciences-highlights-pipeline-progress-in-pah-and-bos-at-the-international-society-for-heart-lung-transplantation-meeting\/","name":"Altavant Sciences Highlights Pipeline Progress in PAH and BOS at the International Society for Heart & Lung Transplantation Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altavant-sciences-highlights-pipeline-progress-in-pah-and-bos-at-the-international-society-for-heart-lung-transplantation-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altavant-sciences-highlights-pipeline-progress-in-pah-and-bos-at-the-international-society-for-heart-lung-transplantation-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMDc0MiM0MTMxMzU3IzIxOTc3MzE=","datePublished":"2021-04-21T12:04:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altavant-sciences-highlights-pipeline-progress-in-pah-and-bos-at-the-international-society-for-heart-lung-transplantation-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/altavant-sciences-highlights-pipeline-progress-in-pah-and-bos-at-the-international-society-for-heart-lung-transplantation-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altavant-sciences-highlights-pipeline-progress-in-pah-and-bos-at-the-international-society-for-heart-lung-transplantation-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMDc0MiM0MTMxMzU3IzIxOTc3MzE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMDc0MiM0MTMxMzU3IzIxOTc3MzE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altavant-sciences-highlights-pipeline-progress-in-pah-and-bos-at-the-international-society-for-heart-lung-transplantation-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Altavant Sciences Highlights Pipeline Progress in PAH and BOS at the International Society for Heart & Lung Transplantation Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/479465","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=479465"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/479465\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=479465"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=479465"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=479465"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}